Effect of Early Versus Delayed Subcutaneous Interferon (scIFN) {beta}-1a to Achieve No Evidence of Disease Activity (NEDA) in Patients with Clinically Isolated Syndrome (CIS): A Post-hoc Analysis of REFLEXION (P3.111)

Conclusions: Early treatment with scIFNβ-1a resulted in more patients achieving NEDA versus DT, maintained up to 5 years post-randomization, with a pronounced effect for more frequent dosing (tiw versus qw), and a clear benefit for treating CIS, including patients meeting the contemporary definition. Study supported by: Merck KGaA, GermanyDisclosure: Dr. Freedman has received research support from Bayer Healthcare and Genzyme. Dr. Comi has received personal compensation for activities with Teva, Novartis, Genzyme, Merck Serono, Biogen, Bayer, Actelion, Almirall, and Serono Symposia International Foundation. Dr. Coyle has received research support from Actelion, Biogen, Genentech/Roche, Novartis, and Opexa. Dr. Liang Chen has received personal compensation for activities with EMD Serono, Inc. as an employee. Dr. Marhardt has personal compensation for activities with Merck as an employee. Dr. Kappos's institution (University Hospital Basel) has received royalty payments from Neurostatus Systems GmbH.
Source: Neurology - Category: Neurology Authors: Tags: MS and CNS Inflammatory Disease: Switching and Comparator Studies I Source Type: research